Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Evive Sells US Rights for Neutropenia Therapy to Aerotech in $236.5 Million Deal

publication date: Nov 16, 2022

Shanghai Evive Biotechnology out-licensed US rights for its neutropenia therapy in patients undergoing chemotherapy, particularly breast cancer. The rights were acquired by Acrotech Biotech of India in a deal worth up to $236.5 million. Evive is a subsidiary of Yifan Pharma. The company developed efbemalenograstim alfa, a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein, using its DikineTM technology platform. Evive was previously known as Generon. More details....

Stock Symbol: (SHZ: 002019)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital